Law360, New York (December 19, 2012, 7:09 PM ET) -- State officials expressed skepticism Wednesday about the U.S. Food and Drug Administration's plan to split oversight of compounding pharmacies following a deadly meningitis outbreak, saying different types of compounding should be more precisely defined.
The FDA convened a meeting with representatives from all 50 states after Commissioner Margaret Hamburg told lawmakers she wanted the agency to have jurisdiction over so-called nontraditional compounders, with states retaining jurisdiction over traditional compounders. Congress is considering an overhaul of compounding regulations in the wake of a meningitis outbreak linked to...
States Push FDA To Hone Compounding Oversight Plan
To view the full article, take a free trial now.
